Cetera Investment Advisers Acquires New Holdings in Cencora, Inc. (NYSE:COR)

Cetera Investment Advisers acquired a new position in Cencora, Inc. (NYSE:COR - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 70,504 shares of the company's stock, valued at approximately $19,607,000.

A number of other institutional investors have also recently bought and sold shares of COR. Cornerstone Planning Group LLC grew its stake in Cencora by 106.7% in the 1st quarter. Cornerstone Planning Group LLC now owns 93 shares of the company's stock valued at $26,000 after buying an additional 48 shares in the last quarter. Hoey Investments Inc. bought a new stake in shares of Cencora during the 1st quarter valued at $28,000. Banque Transatlantique SA purchased a new position in shares of Cencora in the 4th quarter worth about $29,000. Vermillion Wealth Management Inc. bought a new position in shares of Cencora during the fourth quarter valued at $38,000. Finally, Golden State Wealth Management LLC lifted its holdings in Cencora by 157.6% in the first quarter. Golden State Wealth Management LLC now owns 170 shares of the company's stock valued at $47,000 after acquiring an additional 104 shares during the period. Institutional investors own 97.52% of the company's stock.

Wall Street Analyst Weigh In

COR has been the subject of several research analyst reports. Robert W. Baird increased their target price on Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. Citigroup raised their price target on Cencora from $330.00 to $355.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. Jefferies Financial Group lifted their price target on Cencora from $275.00 to $300.00 and gave the company a "hold" rating in a research report on Monday, June 30th. UBS Group boosted their price target on Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a research report on Tuesday, April 29th. Finally, Wells Fargo & Company upgraded Cencora from an "equal weight" rating to an "overweight" rating and lifted their target price for the company from $274.00 to $337.00 in a research report on Tuesday, June 3rd. Three equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, Cencora has a consensus rating of "Moderate Buy" and a consensus price target of $309.83.

Cencora Price Performance

NYSE:COR traded up $2.44 during trading hours on Friday, hitting $288.52. The company's stock had a trading volume of 482,433 shares, compared to its average volume of 1,567,191. The company has a debt-to-equity ratio of 6.01, a quick ratio of 0.52 and a current ratio of 0.87. The business's 50-day moving average is $293.13 and its two-hundred day moving average is $275.35. Cencora, Inc. has a 52-week low of $218.65 and a 52-week high of $309.35. The company has a market capitalization of $55.92 billion, a PE ratio of 33.47, a PEG ratio of 1.45 and a beta of 0.57.

Cencora (NYSE:COR - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, beating the consensus estimate of $4.07 by $0.35. Cencora had a net margin of 0.55% and a return on equity of 344.71%. The firm had revenue of $75.50 billion during the quarter, compared to the consensus estimate of $75.41 billion. During the same period last year, the firm posted $3.80 EPS. The firm's revenue for the quarter was up 10.3% on a year-over-year basis. As a group, research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Shareholders of record on Friday, May 16th were paid a dividend of $0.55 per share. The ex-dividend date was Friday, May 16th. This represents a $2.20 annualized dividend and a yield of 0.8%. Cencora's dividend payout ratio is currently 25.52%.

Insider Activity

In related news, CEO Robert P. Mauch sold 4,968 shares of the firm's stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $294.11, for a total value of $1,461,138.48. Following the transaction, the chief executive officer owned 42,351 shares in the company, valued at approximately $12,455,852.61. This trade represents a 10.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Chairman Steven H. Collis sold 14,578 shares of the company's stock in a transaction dated Tuesday, July 22nd. The stock was sold at an average price of $292.67, for a total value of $4,266,543.26. Following the completion of the sale, the chairman directly owned 309,913 shares of the company's stock, valued at $90,702,237.71. The trade was a 4.49% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 34,125 shares of company stock valued at $9,993,789 over the last 90 days. 10.80% of the stock is currently owned by insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.